Healthcare China is using its vast healthcare data pool to tackle systemic challenges, such as the uneven distribution of medical resources. For example, initiatives like Health China 2030 emphasize the transformative role of AI in enhancing the accessibility, efficiency and quality of medical care in the country. To support this transformation, China developed city-level population health information systems that allow enterprises to access data for business- to-business AI application development. These systems also provide a solid foundation for operations such as training sophisticated AI algorithms, facilitating the digitization of medical records and creating AI-assisted diagnostic tools that improve healthcare accessibility. Selected scenarios and solutions in healthcare TABLE 4 Application Solutions in China Assisted diagnosis and treatment –76% of clinicians in China are confident in using AI for clinical decision-making,45 a figure that is higher than the global average of 61%.46 –Enhance diagnostic accuracy (e.g. the accuracy of judging the absence of pancreatic lesions with AI is as high as 99.9%).47 –Use of AI-driven medical image screening – including subfields such as AI/pathology, AI/ultrasound, AI/endoscopy and AI/electrocardiography – is expanding.48 Assisted treatment –AI technology enhances the automation and efficiency of surgical procedures by autonomously performing denoising and modelling. Healthcare delivery –AI-powered healthcare delivery – in areas like telehealth, personal health record management and clinical decision support systems – is becoming more common. –Virtual care, including for intelligent diagnosis and consultation, remote monitoring, remote surgery and robotic assistance, is another emerging area. –5G-enabled medical robots have been deployed in hospitals to assist with patient care, disinfection and logistics. Drug research and development (R&D) –China’s AI-driven drug R&D sector is projected to reach $187 million in 2024, making up 12% of the global market, with 30% annual growth.49 –Use AI to accelerate first-in-class drug R&D, boosting drug discovery, treatment and healthcare outcomes. –Accelerate R&D for traditional Chinese medicine. Blueprint to Action: China’s Path to AI-Powered Industry Transformation 20

Blueprint to Action Chinas Path to AI-Powered Industry Transformation 2025